Russian drug authorities approve the second Covid-19 Vaccine EpiVacCorona after their early stage of the study, the authorities had given similar approval to their first vaccine a couple of months ago and got criticized in-country and across the globe by scientists.
On Wednesday, the Russian President Vladimir Putin made an announcement during his meeting with his government officials, Russian President said that they need to increase the first and the second vaccine production, he said that the priority would be to supply the vaccine in the Russian market.
Vector Institute in Siberia has developed the recent Covid-19 vaccine EpiVacCorona of Russia, the vaccine has been tested on 100 volunteers in its early stage. The volunteers on whom the vaccine got tested were among 18 to 60 years of age.
The result of the study has not been published yet by the scientist. A scientist who involves in developing the vaccine said that the vaccine has produced sufficient antibodies to keep safe the people who had it from coronavirus, the immunity it develops can last up to 6 months, said interacting with media.
In the month of November or December, an advanced study will be conducted on thousands of volunteers, which is actually necessary for safety and effectiveness establishment.
Tatyana Golikova, the Russian Deputy Prime Minister said that as a volunteer she has taken part in the early trials, she also said that in the advance study of the EpiVacCorona vaccine trial, 40,000 people will be participating. It is still not clear whether the new EpiVacCorona vaccine will available for the wider users while it’s still in the trial phase.
Moscow-based Gamaleya Institute had developed the first Russian vaccine Sputnik V and it was approved by the Russian government in August after the completion of early trials on 76 volunteers. Russian President Vladimir Putin had announced the news just like he did this time on television and said that his daughter had been vaccinated.
Russia has reported the fourth number of Covid-19 cases in the world, it has 1.3 million cases and over 23,000 death cases.